atment Microcyn, said the drug was effective in treating diabetic foot ulcers, the leading cause of leg amputation in the U.S. Oculus's therapy eliminated or reduced infection for three- fourths of patients after 10 days, compared with 57 percent who did that well on a standard saline rinse and levofloxacin, an antibiotic, the company said today in a statement. The benefit was sustained for at least 24 days for all patients on the Oculus drug, and all but one patient in the control group. The results from the 66-patient study mark the first time the Microcyn technology has been tested directly against a standard treatment for infections. If the advantage can be confirmed in larger trials, it could offer a way to avoid overuse of antibiotics and provide a new option for treating diabetic foot ulcers, which lead to 80,000 amputations in the U.S. each year, Oculus said.
